KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Debt: 2010-2024

Historic Non-Current Debt for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $663.7 million.

  • Emergent BioSolutions' Non-Current Debt rose 0.20% to $663.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $663.1 million, marking a year-over-year increase of 0.20%. This contributed to the annual value of $663.7 million for FY2024, which is 48.65% up from last year.
  • As of FY2024, Emergent BioSolutions' Non-Current Debt stood at $663.7 million, which was up 48.65% from $446.5 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Non-Current Debt ranged from a high of $841.0 million in FY2020 and a low of $446.5 million during FY2023.
  • Moreover, its 3-year median value for Non-Current Debt was $448.5 million (2022), whereas its average is $519.6 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Non-Current Debt slumped by 44.59% in 2022, and later skyrocketed by 48.65% in 2024.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Non-Current Debt stood at $841.0 million in 2020, then fell by 3.76% to $809.4 million in 2021, then slumped by 44.59% to $448.5 million in 2022, then dropped by 0.45% to $446.5 million in 2023, then soared by 48.65% to $663.7 million in 2024.